Group 1 included 61 patients ( 59 men and 2 women ; mean age 23.3 + / - 11.2 years ) receiving levofloxacin ( Glevo ) 500 mg/day ; Group 2 comprised 41 patients ( 39 men and 1 woman ; mean age 26.4 + / - 13.4 years ) treated with original levofloxacin 500 mg/day ; Group 3 consisted of 45 patients ( all men ; mean age 23.7 + / - 9.9 years ) on standard therapy .